Elotuzumab(HuLuc 63) is a monoclonal antibody that targets the SLAMF7 receptor.Elotuzumab is a compound that directly activates NK cells and induces antibody-dependent cytotoxicity, and can be used in combination with lenalidomide and dexamethasone (Ld) to treat multiple myeloma.

Elotuzumab（抗SLAMF7）初始两个治疗周期（每周期28天），每周给予10 mg/kg，之后所有随后的周期每两周给予10 mg/kg。采用四种不同的Elotuzumab（抗SLAMF7）联合疗法：1）Elotuzumab（抗SLAMF7）和地塞米松；2）Elotuzumab（抗SLAMF7）、来那度胺和地塞米松；3）Elotuzumab（抗SLAMF7）、波马度胺和地塞米松；4）Elotuzumab（抗SLAMF7）、卡非佐米布、波马度胺和地塞米松。研究发现，不论采用哪种Elotuzumab（抗SLAMF7）联合疗法，所有接受治疗的患者开始Elotuzumab（抗SLAMF7）治疗后磷水平均降低，降幅介于12.5%至44.1%之间。六名参与者（67%）在开始Elotuzumab（抗SLAMF7）治疗后，平均血清磷水平达到或低于2.5 mg/dL。[2]